Mark Lew

6.6k total citations · 1 hit paper
86 papers, 3.5k citations indexed

About

Mark Lew is a scholar working on Neurology, Cellular and Molecular Neuroscience and Epidemiology. According to data from OpenAlex, Mark Lew has authored 86 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Neurology, 19 papers in Cellular and Molecular Neuroscience and 12 papers in Epidemiology. Recurrent topics in Mark Lew's work include Neurological disorders and treatments (51 papers), Parkinson's Disease Mechanisms and Treatments (42 papers) and Botulinum Toxin and Related Neurological Disorders (38 papers). Mark Lew is often cited by papers focused on Neurological disorders and treatments (51 papers), Parkinson's Disease Mechanisms and Treatments (42 papers) and Botulinum Toxin and Related Neurological Disorders (38 papers). Mark Lew collaborates with scholars based in United States, Canada and France. Mark Lew's co-authors include Cheryl Waters, Stewart A. Factor, Joseph Jankovic, Cynthia Comella, James P. Sutton, Robert A. Hauser, Stuart Isaacson, Mitchell F. Brin, Allison Brashear and Scott T. Grafton and has published in prestigious journals such as Science, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Mark Lew

86 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension

2017 268 citations Christopher H. Gibbons, Péter Schmidt et al. Journal of Neurology profile →

Peers

Countries citing papers authored by Mark Lew

Since Specialization

Citations

This map shows the geographic impact of Mark Lew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Lew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Lew more than expected).

Fields of papers citing papers by Mark Lew

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Lew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Lew. The network helps show where Mark Lew may publish in the future.

Co-authorship network of co-authors of Mark Lew

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Lew. A scholar is included among the top collaborators of Mark Lew based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Lew. Mark Lew is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Common mitochondrial deletions in RNA-Seq: evaluation of bulk, single-cell, and spatial transcriptomic datasets 2024 ·Communications Biology ·(unknown), (unknown), (unknown), (unknown), Daniel S. Gerke, (unknown), Zarko Manojlovic, Adolfo Sequeira, Mark Lew, (unknown), Geidy E. Serrano, Thomas G. Beach, Agenor Limón, Marquis P. Vawter, Brooke E. Hjelm	4
2	Apomorphine titration with and without anti-emetic pretreatment in patients with Parkinson’s disease experiencing OFF episodes: A modified Delphi panel 2024 ·SHILAP Revista de lepidopterología ·Stuart Isaacson, Richard B. Dewey, Robert A. Hauser, Daniel Kremens, Rajeev Kumar, Mark Lew, William G. Ondo, Fernando Pagán, Kelly E. Lyons, Rajesh Pahwa	1
3	BoNT clinical trial update: Sialorrhea 2023 ·Toxicon ·(unknown), Mark Lew	1
4	Biomarkers for Parkinson’s Disease with Reflex Tears Stratified by Disease Duration (S16.002) 2022 ·Neurology ·Mark Lew, Srikanth Reddy Janga, (unknown), (unknown), (unknown), (unknown), (unknown), Maria C. Edman, Wendy J. Mack, Curtis T. Okamoto, Sarah F. Hamm‐Alvarez	2
5	Symptomatic Relief in Essential Tremor with Home Use of Non-Invasive Neuromodulation Therapy (435) 2020 ·Neurology ·Rajesh Pahwa, Elizabeth Peckham, Winona Tse, Olga Waln, (unknown), (unknown), Nabila Dahodwala, Michael J. Soileau, Mark Lew, Cameron Dietiker, Nijee Luthra, Stuart Isaacson	1
6	Efficacy of Opicapone Compared to Entacapone in Parkinson’s Patients with Motor Fluctuations and ON Hoehn & Yahr ≤ 2.5: A Post Hoc Analysis of BIPARK-1 (4429) 2020 ·Neurology ·Mark Lew, Robert A. Hauser, Stuart Isaacson, Joaquim J. Ferreira, (unknown), (unknown), Kurt Olson, Olga Klepitskaya, (unknown), Patrício Soares‐da‐Silva, Grace Liang	1
7	Identifying Biomarkers for Parkinson’s Disease with Reflex Tears (S10.001) 2019 ·Neurology ·Mark Lew, (unknown), (unknown), Srikanth Reddy Janga, Wendy J. Mack, Maria C. Edman, Curtis T. Okamoto, Sarah F. Hamm‐Alvarez	1
8	Efficacy results of a 12-month, dose-level blinded study of CVT-301 (levodopa inhalation powder) in patients with Parkinson’s disease (P2.8-048) 2019 ·Neurology ·Eric S. Farbman, Mark Lew, Cheryl Waters, Robert A. Hauser, (unknown), Charles Oh	1
9	Long‐term safety and efficacy of levodopa‐carbidopa intestinal gel in advanced Parkinson's disease 2018 ·Movement Disorders ·Hubert H. Fernandez, James T. Boyd, Victor S.C. Fung, Mark Lew, Ramon L. Rodriguez, John T. Slevin, David G. Standaert, Cindy Zadikoff, Arvydas Vanagunas, Krai Chatamra, Susan Eaton, Maurizio Facheris, Coleen Hall, Weining Robieson, Janet Benesh, Alberto J. Espay	69
10	Tear Proteins as Possible Biomarkers for Parkinson’s Disease 2018 ·Investigative Ophthalmology & Visual Science ·Sarah F. Hamm‐Alvarez, Mark Lew, (unknown), Srikanth Reddy Janga, Mihir Shah, Daniel Freire, (unknown), (unknown), Wendy J. Mack, Curtis T. Okamoto	2
11	The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension breakdown → 2017 ·Journal of Neurology ·Christopher H. Gibbons, Péter Schmidt, Italo Biaggioni, Camille Frazier‐Mills, Roy Freeman, Stuart Isaacson, Beverly Karabin, Louis Kuritzky, Mark Lew, Phillip A. Low, Ali Mehdirad, Satish R. Raj, Steven Vernino, Horacio Kaufmann	268
12	A Phase 2A Trial of the Novel mGluR5‐Negative Allosteric Modulator Dipraglurant for Levodopa‐Induced Dyskinesia in Parkinson's Disease 2016 ·Movement Disorders ·François Tison, Charlotte Keywood, (unknown), Franck Durif, Jean‐Christophe Corvol, Karla Eggert, Mark Lew, Stuart Isaacson, Erwan Bézard, (unknown), Christopher G. Goetz, Claudia Trenkwalder, Olivier Rascol	117
13	Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial 2014 ·The Lancet Neurology ·Robert A. Hauser, C. Warren Olanow, Karl Kieburtz, Emmanuelle Pourcher, Any Docu Axelerad, Mark Lew, (unknown), (unknown), (unknown), (unknown), Christopher Kenney, Stephen I. Bandak	103
14	Rasagiline treatment effects on parkinsonian tremor 2013 ·International Journal of Neuroscience ·Mark Lew	12
15	RimabotulinumtoxinB Effects on Pain Associated with Cervical Dystonia: Results of Placebo and Comparator-Controlled Studies 2010 ·International Journal of Neuroscience ·Mark Lew, (unknown), Yuxin Zhang, (unknown)	13
16	Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia 2010 ·Parkinsonism & Related Disorders ·Daniel Truong, Matthew Brodsky, Mark Lew, Allison Brashear, Joseph Jankovic, Eric Molho, Olga Orlova, Sofia Timerbaeva	119
17	Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease 2008 ·Movement Disorders ·Robert A. Hauser, Mark Lew, Howard I. Hurtig, William G. Ondo, Joanne Wojcieszek, Cheryl Fitzer‐Attas, (unknown)	94
18	Gait and balance dysfunction in adults 2003 ·Current Treatment Options in Neurology ·(unknown), Mark Lew	4
19	Clozapine Treatment of Parkinsonism with Psychosis 1993 ·Journal of the American Geriatrics Society ·Mark Lew, Cheryl Waters	38
20	Consciousness, coma, and the vegetative state: physical basis and definitional character. 1991 ·DigitalGeorgetown (Georgetown University Library) ·(unknown), Mark Lew	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact